Biovitrum and Artemis Collaborate
Stockholm/Cologne - The generation of RNAi-modified transgenic mice for the in vivo functional analysis of selected disease- related genes stands in the focus of a research services agreement signed in July between Biovitrum AB, Stockholm and Artemis Pharmaceuticals GmbH, Cologne. Artemis will generate shRNA knock-down transgenic mice that Biovitrum will use in certain pharmaceutical research programmes. Biovitrum will provide selected shRNA sequences that correspond to genes that may play a central role in human diseases. Artemis will use its proprietary technologies to functionally down-regulate expression of targeted proteins. The triggered biological effects will be analyzed to obtain disease-related data that Biovitrum will apply to its pharmaceutical research. Financial terms were not disclosed.